An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PREVAIL
- Sponsors Johnson & Johnson
- 03 Nov 2017 Results of a post-hoc analysis from NCT01527305 and NCT01051531 studies assessing the impact of once-monthly injection of paliperidone palmitate on functioning in adult patients with schizophrenia in the Asia-Pacific region, published in the Advances in Therapy
- 13 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record